Jefferies Downgrades Regado Biosciences (RGDO) to Hold
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/11/2026
- Wall Street ends down as US-Iran peace optimism fades
- S&P 500 EPS growth above 20% is rare. Why 2027 may be at risk
- Goldman Sachs warns AI investment may be crowding out other business spending
- Why Wednesday's inflation print could provide the next dovish catalyst
- Tesla needs Robotaxi flywheel proof to boost investor conviction: Morgan Stanley
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
- After-Hours Movers: SPCX, AMD, ANET, PINS, APPS, UPST, ZETA, BKNG, LCID, CPNG, MTCH
Worst-Case Scenario Plays Out for Regado Biosciences (RGDO), BMO Capital Says
August 25, 2014 12:01 PM EDTBMO Capital analyst Jim Birchenough reiterated an Underperform rating and $1 price target on Regado Biosciences (NASDAQ: RGDO) after the company announced the permanent termination of the enrollment in the REGULATE-PCI phase 3 trial for the company's lead program, REVOLIXYS Kit. The analyst called it the... More
Deutsche Bank Cuts Regado Biosciences (RGDO) to Hold, Price Target $2
August 25, 2014 9:13 AM EDTDeutsche Bank downgraded Regado Biosciences (NASDAQ: RGDO) from Buy to Hold with a price target of $2.00 (from $14.00). Earlier Regado Biosciences announced the permanent termination of enrollment in its REGULATE-PCI phase 3 trial for its lead program, Revolixys Kit. The decision was made based on a recommendation from the trial's Data and Safety Monitoring Board (DSMB) following their analysis of the data... More
